About Syros Pharmaceuticals
Syros Pharmaceuticals is a company based in Watertown (United States) founded in 2012. Syros Pharmaceuticals has raised $124.4 million across 7 funding rounds from investors including Fidelity Investments, TD Securities and Flagship Pioneering. Syros Pharmaceuticals operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Watertown, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Syros Pharmaceuticals, Inc.
-
Annual Revenue
$9.94 M (USD)-33.23as on Dec 31, 2023
-
Net Profit
-$164.57 M (USD)-73.87as on Dec 31, 2023
-
EBITDA
-$124.25 M (USD)-0.69as on Dec 31, 2023
-
Total Equity Funding
$124.4 M (USD)
in 7 rounds
-
Latest Funding Round
$130 M (USD), Post-IPO
Sep 16, 2022
-
Investors
Fidelity Investments
& 20 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Syros Pharmaceuticals
Syros Pharmaceuticals is a publicly listed company on the OTC with ticker symbol SYRS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Syros Pharmaceuticals
Unlock access to complete
Funding Insights of Syros Pharmaceuticals
Syros Pharmaceuticals has successfully raised a total of $124.4M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $130 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Syros Pharmaceuticals
Syros Pharmaceuticals has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, TD Securities and Flagship Pioneering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Locked | Locked | Locked |
Investor details for Syros Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Syros Pharmaceuticals
Investment portfolio details for Syros Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Syros Pharmaceuticals
Detailed financials for Syros Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Syros Pharmaceuticals Comparisons
Peer comparison for Syros Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Syros Pharmaceuticals
Syros Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Syros Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Syros Pharmaceuticals
Complete news archive for Syros Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syros Pharmaceuticals
Syros Pharmaceuticals was founded in 2012.
Syros Pharmaceuticals is headquartered in Watertown, United States.
Conley Chee is the current CEO of Syros Pharmaceuticals.
Syros Pharmaceuticals is a funded company, having raised a total of $124.4M across 7 funding rounds to date.
Annual revenue of Syros Pharmaceuticals is $9.94M as on Dec 31, 2023.
Syros Pharmaceuticals was founded in 2012 and is headquartered in Watertown, United States. Operations focus on the biotechnology sector, where small molecule therapeutics are developed to address cancer and genetic diseases. The lead program, SY-1425, targets relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome as a selective RARa agonist. Additionally, SY-1365 serves as a selective CDK7 inhibitor for acute leukemia treatment.
Syros Pharmaceuticals's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Yes, Syros Pharmaceuticals is publicly traded on OTC under the ticker symbol SYRS.
Syros Pharmaceuticals has 21 investors. Key investors include Fidelity Investments, TD Securities, Flagship Pioneering, Orbimed, and Arch Venture Partners.
The ticker symbol of Syros Pharmaceuticals is SYRS on OTC.